|
|
|
|
||
Andexxa Highlighted as a First-Line Factor Xa Reversal Option by the American College of Emergency PhysiciansThe article below is from Nov 15th but I don't recall seeing it on our IV boards. Nov. 15, 2019 /PRNewswire/ Portola Pharmaceuticals, Inc.® (PTLA) today announced that Annals of Emergency Medicine, the journal of the American College of Emergency Physicians (ACEP), published a multidisciplinary anticoagulant reversal and replacement guidance statement. The guidance statement is supported by literature and consensus definitions to support evaluation and treatment of the bleeding and nonbleeding patient requiring emergency invasive procedures. In the guidance statement, ACEP highlighted Andexxa® [coagulation factor Xa (recombinant), inactivated-zhzo] as a first-in-line, U.S. Food and Drug Administration (FDA) approved reversal agent for patients treated with apixaban or rivaroxaban, as compared to 4F-PCC, which are highlighted as a second-in-line option for Factor Xa reversal and recommended for use only if Andexxa is not available. Boston, MA. "This new guidance aligns with clinical practice at our institution, where we are seeing positive clinical outcomes in patients treated with Andexxa." As the number of patients taking Factor Xa inhibitors continues to grow, it is encouraging that many societies, now including ACEP, have officially recognized the importance of specific, rapid anticoagulation reversal when life-threatening bleeding occurs," said leading author Christoper W. Baugh, M.D., M.B.A., Department of Emergency Medicine, Brigham and Women's Hospital, Boston, MA. A multidisciplinary expert panel of academic and community physicians defined the consensus recommendations through the creation and interpretation of a consensus anticoagulation reversal or replacement decision tree and stepwise guidance framework to aid the emergency physician's evaluation and management of the bleeding patient receiving an anticoagulant. The expert panel also reached agreement on key definitions of life-threatening bleeding, bleeding at a critical site, and emergency surgery or urgent invasive procedure to support decision tree interpretation. Portola's president and chief executive officer. "We are encouraged by ACEP's characterization of Andexxa as a Tier 1 recommendation 'most aligned with FDA-approved indications and the highest quality of evidence supporting their use' as it highlights its potential to benefit thousands of patients facing life-threatening bleeding associated with the use of rivaroxaban or apixaban.""This guidance further exemplifies the breakthrough innovation of Andexxa and the clinical value of rapidly reversing the anticoagulant effects of Factor Xa inhibitors rivaroxaban or apixaban in the event of life-threatening or uncontrolled bleeding," said Scott Garland, Portola's president and chief executive officer. The consensus statement is available for reference
at: https://www.annemergmed.com/article/S0196-0644(19)31181-3/fulltext. " data-reactid="28" style="color: #26282a; font-family: "Helvetica Neue", Helvetica, Arial, sans-serif; font-size: 10pt; background-color: #ffffff;"> https://www.annemergmed.com/article/S0196-0644(19)31181-3/fulltext About Factor Xa Inhibitor-Related Bleeding The use of Factor Xa inhibitors is growing rapidly because of their efficacy and safety profile compared to enoxaparin and warfarin in preventing and treating thromboembolic conditions such as stroke, pulmonary embolism and venous thromboembolism (VTE). This growth has come with a related increase in the incidence of hospital admissions and deaths related to bleeding, the major complication of anticoagulation. In 2017, there were approximately 150,000 hospital admissions attributable to Factor Xa inhibitor-related bleeding and approximately 2,100 bleeding-related deaths per month in the U.S. |
return to message board, top of board |
Msg # | Subject | Author | Recs | Date Posted |
6599 | Re: Andexxa Highlighted as a First-Line Factor Xa Reversal Option by the American College of Emergency Physicians | JoeFlow | 2 | 11/29/2019 11:12:39 AM |